Clinical trial
Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
NCT00060476 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00060476 |
|---|---|
| Title | Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201) |
| Official title | A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib in Decreasing the Risk of Prostate Cancer (ViP Study) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | rofecoxib, Comparator: placebo (unspecified) |
| Enrollment | 15,000 |
| Start date | Jan 8, 2003 |
| Primary completion | Dec 8, 2004 |
| Completion | Dec 8, 2004 |
| First posted | May 7, 2003 |
| Last update posted | May 9, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: